Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved January 5, 2022 by Businesswire [#item_full_content] Related Spread the word
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish